Abstract Library

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#3554 Stereotactic radiosurgery of brain metastases in large cell neuroendocrine carcinoma of the lung

Introduction: Stereotactic radiosurgery (SRS) is an established treatment of brain metastases (BM) in non-small cell lung cancer (NSCLC) whereas small cell lung cancer (SCLC) is usually treated with whole-brain irradiation (WBI). There is no consensus on treatment of BM in large cell neuroendocrine carcinoma of the lung (LCNEC).

Conference:

Presenting Author: Suppli M

Authors: Suppli M, Langer S, Persson G, Møller S,

Keywords: LCNEC, Radiosurgery, brain metastasis, radiotherapy,

#3158 Incidence of brain metastases (BMs) and outcomes in patients (pts) with extrapulmonary neuroendocrine neoplasms (EP-NENs)

Introduction: The incidence, management and outcomes of pts with EP-NENs and BMs are unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kapacee Z, Dawod M, Allison J, Frizziero M, Chakrabarty B,

Keywords: brain metastases, extrapulmonary NENs, radiotherapy, whole brain radiotherapy, survival, grade 3 NEC,

#3156 To determine the true incidence of brain metastases in atypical lung neuroendocrine tumors and explore factors that increase the risk of intracranial disease

Introduction: Lung neuroendocrine tumors (NETs) make up 25% of all NETs. Typical carcinoid (TC) and atypical carcinoid (AC) account for 2% and 0.2% of all lung NETs respectively, and AC tend to be more aggressive. Although both can metastasise, AC are more likely; common sites include bone and liver. Currently, brain imaging is not included in the work-up of TC/AC, as

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Jones J, Spurgeon L, Shaheen F, Lewis A, Mansoor W,

Keywords: typical carcinoid, atypical carcinoid, brain metastases, Ki67,

#2763 Incidence and Outcome of Brain Metastasis in Patients Diagnosed with Neuroendocrine Neoplasm

Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: brain metastasis, grade 3 tumors,